tbuckley/cabot-search huggingface dataset:
123I-MIBG SPECT/CT and 18F-FDG PET in vivo imaging of the TH-MYCN neuroblastoma transgenic mouse
Authors: Selma Masic, Youngho Seo, Dong-Wei Gao, Matt Grimmer, Kim Nguyen, Slava Yakovenko, Bruce Hasegawa, Henry Vanbrocklin, Katherine Matthay, William Weiss, Louis Chesler
Journal: Cancer Research (2008)

LB-296  Introduction: Meta-iodobenzylguanidine (MIBG) is metabolized by neuroectodermal cells expressing the noradrenaline transporter. 123I-MIBG imaging is therefore a powerful clinical imaging modality for human neuroblastoma, a tumor of neuronal origin. 18F- fluorodeoxyglucose (FDG) PET imaging is under evaluation as an additional imaging agent for human neuroblastoma. Small animal radionuclide imaging of genetically engineered murine cancer models (GEMM’s) has significant potential as an approach that can provide critical pre-clinical data necessary for streamlined introduction of novel imaging techniques and therapeutics into human clinical trials. We therefore assessed the ability of 123I-MIBG SPECT/CT and 18F-FDG PET imaging to detect tumor formation in a well-characterized GEMM of neuroblastoma (TH-MYCN).  Approach/Results: Small animal SPECT/CT (FLEX™, Gamma Medica-Ideas, Inc., Northridge, CA) and PET (Inveon, Siemens Medical Solutions, Malvern, PA) systems were used, respectively, to image the biodistribution and tumor uptake of targeted (123I-MIBG) and semi-targeted (18F-FDG) radiopharmaceuticals in spontaneously arising murine TH-MYCN neuroblastomas. The tumor- and organ-specific radio-label uptake (sensitivity and background) associated with each modality was compared, and areas of radiopharmaceutical incorporation were correlated to anatomic tumor location upon necropsy. Scintillation counting of radio-label uptake in tumor and relevant organs was performed and was correlated to the associated radiologic images.  Conclusions: 123I-MIBG SPECT/CT and 18F-FDG PET imaging are reliable and practical methods for the detection of murine neuroblastoma in the TH-MYCN GEMM. Both radiopharmaceuticals were specifically incorporated into primary tumors with low background. The sensitivity of 123I-MIBG imaging is quantitatively greater than that of 18F-FDG PET imaging, with lower non-specific background. Potential applications of this approach include assessment of tumor formation, progression and response to chemotherapeutics. When used in conjunction with transgenic animal model systems, these approaches will offer unique insights into tumor physiology and response to therapy.
P2.01-62 Extracellular Vesicle-Based Egfr Genotyping in Bronchoalveolar Lavage Fluid from Non-Small Cell Lung Cancer Patients
Authors: J.S. Lee, J.Y. Hur, I.A. Kim, H.J. Kim, W.S. Kim, K.Y. Lee
Journal: Journal of Thoracic Oncology (2018)
P3.01-22 An Exploratory Analysis of PD-L1 Expression and Smoking History in a Cohort of Advanced Non-Small Cell Lung Cancer Patients
Authors: M. Decatris, P. Taniere, M. Hayes, J. Thomas, K. Gaikwad, M. Kalkat, K. Birchall, J. Osbaldiston, A. Phillips, P. Ryan, N. Reed, I. Du Rand
Journal: Journal of Thoracic Oncology (2018)
John Kenelm Guly
Authors: Henry Guly
Journal: BMJ (2018)

After house officer posts at St Mary’s and Colindale hospitals, John Kenelm Guly entered general practice in 1953. He was a trainee to Dr John Ford and later joined him in a partnership. His career reflects the changes in general practice that occurred over the following 35 years. When he started, his son remembers hurried mealtimes, as, while the family was eating, patients could be seen, through net curtains, gathering in the conservatory, which acted as a waiting room. When the meal was over, the table was pushed to one side, a desk and examination couch were rolled out; the dining room became a consulting room and the children, elsewhere in the …
P1.16-24 Impact of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single Fraction SBRT for Stage I Non-Small Cell Lung Cancer
Authors: B. Manyam, G. Videtic, K. Verdecchia, C. Reddy, N. Woody, T. Zhuang, K. Stephans, A. Juloori
Journal: Journal of Thoracic Oncology (2018)
Evaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade
Authors: H. Jackson, S. Bhattacharya, P. Bojczuk, D. Kilian, L. Seestaller Wehr, A. Hahn, H. Shi, M. Bi, M. Adam, J. Jing, P. Morley, C. Hopson, E. Paul, A. Hoos, J. Smothers, R. Srinivasan, N. Yanamandra
Journal: Annals of Oncology (2018)
Randomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type
Authors: F. Grossi, P. Jaskiewicz, E. Pichon, G. Czyzewicz, D.M. Kowalski, L. Ciuffreda, R. Garcia Gomez, S. Caruso, J. Bosch Barrera, C. Ta Thanh Minh, S. Gautier, H. Hervieu, S. Henriet, G. De Castro Jr
Journal: Annals of Oncology (2018)
End of life resource utilization among patients receiving immunotherapy for advanced cancer
Authors: J.T. Burkart, S. Patel, A.M. Noonan, P. Monk, C.J. Presley, T. Olencki, K.L. Kendra, G.A. Otterson, J. Gustin, L. Wei, D.H. Owen
Journal: Annals of Oncology (2018)
Phase I, open-label ascending dose trial of anti–CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti–PD-1/PD-L1 therapy
Authors: B.A. Wilky, P. Kumthekar, R. Wesolowski, J.J. Hwang, S.I. Park, G. Yuan, C.D. Dupont, M. Lim, O. Shebanova, J.-M. Cuillerot, E. Dow, W. Ortuzar, J.J. Raizer, E. Drouin, N. Wilson, A.M. Gonzalez, J.M. Goldberg, J.S. Buell, R.B. Stein, H. Youssoufian
Journal: Annals of Oncology (2018)
MS32.01 Genetic Mouse Models (GEMMS)
Authors: G. Mollaoglu, M. Chalishazar, F. Huang, M. Guthrie, S. Bohm, J. Br€Agelmann, T. Sen, L. Byers, J. Johnson, R. Wechsler-Reya, A. Gazdar, R. Deberardinis, M. Sos, T. Oliver
Journal: Journal of Thoracic Oncology (2018)
TNBC universe: A monocentric retrospective analyses of TILs and AR as prognostic markers
Authors: A. Losurdo, R. De Sanctis, B. Fernandes, V. Errico, A. Sagona, G. Masci, M. Zuradelli, E. Agostinetto, R. Torrisi, W. Gatzemeier, A. Testori, M. Roncalli, M. Alloisio, C. Tinterri, A. Santoro
Journal: Annals of Oncology (2018)
Severe acute alcoholic hepatitis and liver transplant: A never-ending mournful story
Authors: Aiman Obed, Abdalla Bashir, Steffen Stern, Anwar Jarrad
Journal: Clinical and Molecular Hepatology (2018)

Severe acute alcoholic liver disease (SAAH) unresponsive to medical therapy shows one-year-mortality rates of up to 90%. Most transplant centers request six months of alcohol abstinence prior to transplantation, the so-called "6-month rule." This regulation is not based on strong evidence, repeatedly making it a topic of controversial debates. The majority of patients with SAAH will die before fulfilling the 6-month rule. Therefore, liver transplantation (LT) protocols are becoming more flexible towards the rigid abstinence regulation, especially concerning SAAH patients. We conducted a literature review regarding LT in SAAH and its outcomes, including post-transplant mortality and recidivism. We studied available data on PubMed from 2011 and onwards whilst including articles dealing with genetic components, medical therapy and historic snapshots of alcoholism. Emerging studies recommend LT in SAAH not responding to medical therapies even without realizing the required abstinence period, since the majority of these patients would die within 6 months. SAAH without response to medical therapy has one-year-mortality rates of up to 90%. The 6-month rule is not based on strong evidence and is repeatedly a topic of controversial debates. There is genetic linkage to alcoholism and medical therapy is not as effective as estimated, yet. The 6-months-regulation has not shown to evidently decrease the risk of recidivism post-LT, which is a lifesaving treatment in SAAH patients. Insisting on rigid sobriety rules results in excluding patients with a low risk of recidivism from being transplanted. Moreover, the genetic linkage of alcoholism must be recognized.
ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)
Authors: M.R. Smith, C.C. Parker, F. Saad, K. Miller, B. Tombal, Q.S. Ng, M. Bögemann, V. Matveev, J.M. Piulats, L.E. Zucca, A. Heidenreich, Y. Kakehi, A. Zhang, H. Krissel, J. Shen, V. Wagner, C. Higano
Journal: Annals of Oncology (2018)
Association between patient reported quality of life (QOL) and survival: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer
Authors: A.K. Morgans, Y.-H. Chen, D. Jerrard, M.A. Carducci, R. Dipaola, L. Wagner, D. Cella, C. Sweeney
Journal: Annals of Oncology (2018)
Retrospective study of paclitaxel in advanced therapy lines in the treatment of SCLC
Authors: D. von Eiff, F. Bozorgmehr, P. Christopoulos, I. Chung, D. Bernhardt, S. Rieken, S. Liersch, T. Muley, S. Kobinger, M. Thomas, M. Steins
Journal: Annals of Oncology (2018)
P1.05-09 Dielectric Property Test for the Rapid Differential Diagnosis of Lung Nodules/Mass
Authors: D. Lu, X. Dong, S. Feng, X. Liu, X. Shi, H. Wu, D. Diao, P. Ren, R. Cai, Z. Huang, H. Wang, K. Cai, X. Xin, H. Ji, Z. Wang, C. Hong, Y. Sun, X. Yu
Journal: Journal of Thoracic Oncology (2018)
Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer
Authors: Y.-J. Bang, T. Doi, S. Kondo, H.C. Chung, K. Muro, I. Dussault, C. Helwig, M. Osada, Y.-K. Kang
Journal: Annals of Oncology (2018)
P1.16-26 Safety of SABR (Stereotactic Ablative Body Radiotherapy) for Central Non-Small Cell Lung Cancers (cNSCLC) with 50 Gray in 5 Fractions (50Gy/5f)
Authors: R. Rulach, J. Hicks, G. Lumsden, S. Mckay, V. Maclaren, J. Macphee, K. Moore, M. Omand, M. Sproule, S. Currie, A. Aitken, R. Ferguson, P. Houston, R. Valentine, S. Harrow
Journal: Journal of Thoracic Oncology (2018)
P2.17-04 Imiquimod Attenuates Radiation-Induced Pulmonary Fibrosis
Authors: M. Calik, G. Yavas, E. Celik, C. Yavas, G. Calik, M. Sargon, Y. Sanli, H. Esme, O. Ata
Journal: Journal of Thoracic Oncology (2018)
Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Authors: C.-H. Lee, R.J. Motzer, H. Glen, M.D. Michaelson, J. Larkin, Y. Minoshima, M. Kanekiyo, R. Dairiki, P. Sachdev, C.E. Dutcus, Y. Funahashi, M.H. Voss
Journal: Annals of Oncology (2018)
P1.16-27 Using Rates of Clinical Brachial Plexopathy after Lung SBRT to Better Characterize the Tolerance of the Brachial Plexus
Authors: K. Verdecchia, B. Manyam, C. Reddy, K. Rogacki, T. Zhuang, G. Videtic, K. Stephans
Journal: Journal of Thoracic Oncology (2018)
MA13.07 Diagnostic Yield of N3 Hilar Staging by Endobronchial Ultrasonography (EBUS) in Lung Cancer
Authors: J. Bordas Martinez, J.L. Vercher Conejero, G. Rodriguez Gonzalez, C. Martin Cabeza, N. Cubero De Frutos, R. Lopez Lisbona, M. Diez Ferrer, P. Notta, R. Llatjos Sanuy, J. Dorca Sargatal, A. Rosell Gratacos
Journal: Journal of Thoracic Oncology (2018)
Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort
Authors: W. Jacot, G. Louvel, A. Darlix, J. Fraisse, E. Brain, M. Debled, M.A. Mouret Reynier, A. Goncalves, F. Dalenc, P. Augereau, J.-M. Ferrero, C. Levy, J.-D. Fumet, C. Jouannaud, C. Veyret, V. Dieras, M. Robain, C. Courtinard, D. Pasquier, T. Bachelot
Journal: Annals of Oncology (2018)
Abstract 18294: Long-Term Outcomes of Diabetic Patients Undergoing Percutaneous Intervention for Popliteal and Infrapopliteal Peripheral Arterial Disease-Insights From the Laser in Infra-Popliteal & Popliteal Stenosis (LIPS) Study
Authors: Saroj Neupane, Sushruth Edla, Eesha Maidona, Susanna M Szpunar, Thomas A Lalonde, Rajendra H Mehta, Howard S Rosman, Hiroshi Yamasaki
Journal: Circulation (2016)

Introduction: Patients (pts) with diabetes mellitus (DM) are more likely to have popliteal and infrapopliteal peripheral arterial disease (PAD). Clinical features and outcomes of these pts are less well known. Methods: We evaluated the data of the LIPS study to examine the clinical features and adjusted long-term outcomes of pts with and without DM undergoing popliteal and infrapopliteal peripheral vascular interventions (PVI). Results: Of 714 pts in the study, 418 had DM (59%). Compared to the pts without DM, those with DM despite being younger (73±11.3 vs. 70±11.2 yrs) had higher comorbidities - CAD (62 vs. 76%), CHF (22 vs. 30%), ESRD (3 vs. 17%), and prior contralateral limb amputation (2 vs. 15%). All cause mortality (36 vs. 26%; [OR=1.61, 95% CI 1.13-2.29]) and major adverse vascular events (composite of death, major amputation and repeat revascularization; (54 vs. 40%; [OR=1.97, 95% CI 1.44-2.69]) were higher in DM pts (mean follow up 36±20 months, Figure 1). Major amputation rate in the ipsilatera...
Activity &amp; safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, &amp; gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
Authors: J.C. Yao, J. Strosberg, N. Fazio, M.E. Pavel, P. Ruszniewski, E. Bergsland, D. Li, S. Tafuto, N. Raj, D. Campana, S. Hijioka, M. Raderer, R. Guimbaud, P. Gajate, S. Pusceddu, A. Reising, E. Degtyarev, B. Mookerjee, P. Aimone, S. Singh
Journal: Annals of Oncology (2018)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Authors: Courtney D. DiNardo, Keith Pratz, Vinod Pullarkat, Brian A. Jonas, Martha Arellano, Pamela S. Becker, Olga Frankfurt, Marina Konopleva, Andrew H. Wei, Hagop M. Kantarjian, Tu Xu, Wan-Jen Hong, Brenda Chyla, Jalaja Potluri, Daniel A. Pollyea, Anthony Letai
Journal: Blood (2018)
P1.01-104 Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women with Metastatic Non-Squamous NSCLC
Authors: P. Young, D. Marquez, Z. Noor, R. Callahan, B. Jones, D. Wong, J.W. Goldman, S. Applebaum, R. Rausch, C. Yanes, S. Bueno, N. Garban, D. Elashoff, E. Garon, R. Pietras
Journal: Journal of Thoracic Oncology (2018)
P2.01-38 Sarcopenia is Associated with Metastatic Burden and is a Negative Prognostic Factor in Metastatic Non-Small Cell Lung Cancer
Authors: C. Glisch, K. Monahan, D. Baruah, J. Thompson, Z. Yin, A. Szabo, J. Patel, S. Menon
Journal: Journal of Thoracic Oncology (2018)
MA05.03 Immune Microenvironment and its Association with Adjuvant Chemotherapy Benefit in Locoregionally Advanced Lung Adenocarcinoma
Authors: R. Vaghjiani, T. Eguchi, N. Chintala, X. Li, R. Aly, K. Emoto, K.S. Tan, D. Jones, P. Adusumilli
Journal: Journal of Thoracic Oncology (2018)
Multicenter phase II trial of nab-paclitaxel and cisplatin (AP) followed by chemoradiation therapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC)
Authors: D. Adkins, J. Ley, H.A. Gay, M. Daly, R. Jackson, J. Rich, P. Pipkorn, R.C. Paniello, K. Trinkaus, P. Neupane, J. Zevallos, W. Thorstad, P. Oppelt
Journal: Annals of Oncology (2018)
Abstract 16258: Clinical Trials in Heart Failure: Where Are We?
Authors: Naga Venkata K Pothineni, Ajoe J Kattoor, Swathi Kovelamudi, Satish Kenchaiah
Journal: Circulation (2016)

Introduction: Heart failure (HF) is a global health problem. We sought to examine the focus of ongoing clinical trials in HF and compare ongoing trials with population prevalence of HF with preserv...
Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial
Authors: A.M. Morelli, M.R. Migliorino, A. Morabito, R. Chiari, F. Grossi, P. Bordi, F. Di Costanzo, A. Delmonte, G. Romano, A. Misino, V. Scotti, V. Gregorc, S. Pisconti, G.L. Ceresoli, A. Del Conte, I. Colantonio, L. Ciuffreda, E. Capelletto, I. Stura, S. Novello
Journal: Annals of Oncology (2018)
Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Authors: T. Aparicio, A. Darut Jouve, F. Khemissa, C. Montérymard, P. Artru, L. Cany, O. Romano, B. Valenza, C. Le Foll, C. Delbaldo, C. Falandry, M. Duluc, Y. Rinaldi, J.L. Legoux, M. Ben Abdelghani, E. Assenat, M. Dhooge, D. Smith, G. Des Guetz, C. Lepage
Journal: Annals of Oncology (2018)
Paclitaxel in combination with anti-EGFR therapy as induction chemotherapy for patients unfit for cisplatin with locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Authors: J.A. Marín, M. Oliva Bernal, M. Plana Serrahima, M. Ferrer, N. Vilariño Quintela, S. Vazquez, E. Vilajosana, A. Lozano, J. Nogués, A. Marí, O. Bermejo, R. Mesia Nin, M. Taberna Sanz
Journal: Annals of Oncology (2018)
P1.01-92 A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations
Authors: K. Suzuki, H. Imai, K. Kaira, M. Anzai, T. Tsuda, T. Ishizuka, T. Kuwako, I. Naruse, K. Nemoto, J. Uchino, N. Morozumi, S. Ishihara, K. Minato, T. Hisada
Journal: Journal of Thoracic Oncology (2018)
Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study
Authors: H. Blons, J.-B. Oudart, J.-P. Merlio, S. Hominal, F. de Fraipont, D. Debieuvre, F. Escande, C. Audigier Valette, P.-P. Bringuier, S. Moreau Fraboulet, L. Ouafik, D. Moro-Sibilot, A. Lemoine, A. Langlais, P. Missy, F. Morin, P.-J. Souquet, F. Barlesi, J. Cadranel, M. Beau-Faller
Journal: Annals of Oncology (2018)
Screening for Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults
Authors: Cynthia Feltner, Ina Wallace, Nancy Berkman, Christine E. Kistler, Jennifer Cook Middleton, Collen Barclay, Laura Higginbotham, Joshua T. Green, Daniel E. Jonas
Journal: JAMA (2018)

<h3>Importance</h3> Intimate partner violence (IPV), elder abuse, and abuse of vulnerable adults are common and result in adverse health outcomes. <h3>Objective</h3> To review the evidence on screening and interventions for IPV, elder abuse, and abuse of vulnerable adults to inform the US Preventive Services Task Force. <h3>Data Sources</h3> MEDLINE, Cochrane Library, EMBASE, and trial registries through October 4, 2017; references; experts; literature surveillance through August 1, 2018. <h3>Study Selection</h3> English-language randomized clinical trials (RCTs), studies evaluating test accuracy, and cohort studies with a concurrent control group assessing harms. <h3>Data Extraction and Synthesis</h3> Dual review of titles and abstracts, full-text articles, and study quality; qualitative synthesis of findings. Data were not pooled, primarily because of heterogeneity of populations, interventions, and outcomes. <h3>Main Outcomes and Measures</h3> Abuse or neglect, morbidity caused by abuse, test accuracy, and harms. <h3>Results</h3> Thirty studies were included (N = 14 959). Three RCTs (n = 3759) compared IPV screening with no screening; none found significant improvements in outcomes (eg, IPV or quality of life) over 3 to 18 months and 2 (n = 935) reported no harms of screening. Nine studies assessed tools to detect any past-year or current IPV in women; for past-year IPV (5 studies [n = 6331]), sensitivity of 5 tools ranged from 65% to 87% and specificity ranged from 80% to 95%. The accuracy of 5 tools (4 studies [n = 1795]) for detecting current abuse varied widely; sensitivity ranged from 46% to 94% and specificity ranged from 38% to 95%. Eleven RCTs (n = 6740) evaluated interventions for women with screen-detected IPV. Two enrolling pregnant women (n = 575) found significantly less IPV among women in the intervention group: 1 home visiting intervention (standardized mean difference [SMD], −0.34 [95% CI, −0.59 to −0.08]) and 1 behavioral counseling intervention for multiple risks (IPV, smoking, depression, tobacco exposure) (SMD, −0.40 [95% CI, −0.68 to −0.12]). No studies evaluated screening or interventions for elder abuse or abuse of vulnerable adults. One study assessing a screening tool for elder abuse had poor accuracy (sensitivity, 46% and specificity, 73% for detecting physical or verbal abuse). <h3>Conclusions and Relevance</h3> Although available screening tools may reasonably identify women experiencing IPV, trials of IPV screening in adult women did not show a reduction in IPV or improvement in quality of life over 3 to 18 months. Limited evidence suggested that home visiting and behavioral counseling interventions that address multiple risk factors may lead to reduced IPV among pregnant or postpartum women. No studies assessed screening or treatment for elder abuse and abuse of vulnerable adults.
MA11.07 Expression of LAG-3 and NY-ESO-1 In Tumor Cells is Promising Biomarker Predicting Durable Clinical Benefit of PD-1 Blockade in Advanced NSCLC
Authors: H.R. Jang, S.H. Kim, K.J. Suh, Y.J. Kim, M.S. Kim, B. Keam, T.M. Kim, J. Chung, D. Kim, D.S. Heo, J. Lee
Journal: Journal of Thoracic Oncology (2018)
Abstract 19070: Postmortem Genetic Testing: Contributions to Revealing Cause of Death and Familial Cascade Testing
Authors: Jessica Gage, Benjamin Feldmann, Lily Hoang, Jill Dolinsky, Tami Johnston, Christian Antolik
Journal: Circulation (2017)

Postmortem genetic testing, often called the “molecular autopsy” can identify cause of death in individuals who die suddenly and unexpectedly. Genetic testing can also lead to cascade testing of family members, which can determine who in a family needs preventative screening and/or management, and ultimately save lives. We have analyzed DNA samples from 64 postmortem cases between August 2012 and October 2016 with multigene panel testing using Next Generation Sequencing and targeted chromosomal microarray at our diagnostic laboratory. Clinical history was taken from test order forms, pedigrees, and clinic notes. Other than sudden cardiac arrest, which was present in 95% of cases (36/38 cases in which this was indicated on the test order form), a personal clinical history of cardiomyopathy, arrhythmia, or both cardiomyopathy and arrhythmia was the most common indication for testing; approximately 30% of probands had cardiomyopathy, 15% had arrhythmia, and 33% had both cardiomyopathy and arrhythmia. Of the ...
Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies
Authors: S.J. Klempner, J. Bendell, V. Meucci Villaflor, L. Tenner, S. Stein, C.A. Sirard, W. Newman, M. Kagey, K. Schlienger, J. Strickler
Journal: Annals of Oncology (2018)
Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)
Authors: S. Peters, A.T. Shaw, B. Besse, E. Felip, B.J. Solomon, R.A. Soo, A. Bearz, S.M. Gadgee, C.-C. Lin, S. Kao, T. Seto, E.T. Masters, A. Abbattista, J.S. Clancy, H. Thurm, A. Reisman, D.R. Camidge
Journal: Annals of Oncology (2018)
MA20.09 Improved Lung Cancer and Mortality Prediction Accuracy Using Survival Models Based on Semi-Automatic CT Image Measurements
Authors: A. Schreuder, C. Jacobs, N. Lessmann, E. Scholten, I. Isgum, M. Prokop, C. Schaefer-Prokop, B. Van Ginneken
Journal: Journal of Thoracic Oncology (2018)
P2.10-08 Smoking Prevention Project in School Population: My Health Is in My Own Hands
Authors: T. Kovacevic, D. Bokan, B. Zaric, V. Stojsic, T. Boskovic, P. Simurdic, A. Andjelkovic, I. Ergelasev, J. Stanic
Journal: Journal of Thoracic Oncology (2018)